Relationship between increased serum neurofilament light chain and glial fibrillary acidic protein levels with non-motor symptoms in patients with Parkinson's disease

被引:0
作者
Yin, Peixiao [1 ,2 ]
Niu, Xuebin [1 ,2 ]
Guan, Chenyang [1 ,2 ]
Zhang, Zixuan [1 ,2 ]
Liu, Yuning [1 ,2 ]
Li, Jinyu [1 ,2 ]
Cui, Guiyun [1 ,2 ]
Zan, Kun [1 ,2 ,3 ]
Xu, Chuanying [1 ,2 ,3 ]
机构
[1] Xuzhou Med Univ, Dept Neurol, Affiliated Hosp, Xuzhou, Peoples R China
[2] Xuzhou Med Univ, Clin Coll 1, Dept Neurol, Xuzhou, Peoples R China
[3] Xuzhou Med Univ, Affiliated Hosp, Dept Neurol, 99 West Huaihai Rd, Xuzhou 221000, Jiangsu, Peoples R China
关键词
glial fibrillary acidic protein; neurofilament light chain; non-motor symptoms; Parkinson's disease; PARKINSONS-DISEASE; RATING-SCALE;
D O I
10.1111/psyg.13088
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: This study set out to investigate the relationship between serum neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and various non-motor symptoms (NMSs) in patients with Parkinson's disease (PD). Methods: The study included 37 healthy controls (HCs) and 51 PD patients. Clinical assessments of PD symptoms were conducted for all PD patients. The NMSS was utilised to evaluate the NMS burden (NMSB) in individuals. Based on the severity of NMSB, we further categorised the PD group into two subgroups: mild-moderate NMSB group and severe-very severe NMSB group. The amounts of NFL and GFAP in the serum were measured using an extremely sensitive single molecule array (Simoa) method. Statistical analyses were performed on the collected data using SPSS 26.0 and R (version 3.6.3). Results: Serum GFAP and NFL levels in the PD group with severe-very severe NMSB were significantly higher than those in the mild-moderate NMSB group (GFAP: P < 0.007; NFL: P < 0.009). Serum NFL and GFAP levels had positive correlations with NMSS total scores (GFAP: r = 0.326, P = 0.020; NFL: r = 0.318, P = 0.023) and multiple subdomains. The relationship between the attention/memory domains of NMSS and NFL levels is significantly positive (r = 0.283, P = 0.044). Similarly, the mood/apathy domains of NMSS are also significantly positively correlated with GFAP levels (r = 0.441, P = 0.001). Patients with emotional problems or cognitive impairment had higher GFAP or NFL levels, respectively. Furthermore, it has been demonstrated that NMSs play a mediating role in the quality of life of patients with PD. Moreover, the combination of NFL and GFAP has proven to be more effective than using a single component in identifying PD patients with severe-very severe NMSB. Conclusions: The severity of NMSs in PD patients, particularly cognitive and emotional symptoms, was found to be associated with the levels of serum NFL and GFAP. This study marks the first attempt to examine the connection between NMSs of PD and the simultaneous identification of NFL and GFAP levels.
引用
收藏
页码:415 / 425
页数:11
相关论文
共 38 条
[1]   Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease [J].
Aamodt, Whitley W. ;
Waligorska, Teresa ;
Shen, Junchao ;
Tropea, Thomas F. ;
Siderowf, Andrew ;
Weintraub, Daniel ;
Grossman, Murray ;
Irwin, David ;
Wolk, David A. ;
Xie, Sharon X. ;
Trojanowski, John Q. ;
Shaw, Leslie M. ;
Chen-Plotkin, Alice S. .
MOVEMENT DISORDERS, 2021, 36 (12) :2945-2950
[2]   Blood GFAP as an emerging biomarker in brain and spinal cord disorders [J].
Abdelhak, Ahmed ;
Foschi, Matteo ;
Abu-Rumeileh, Samir ;
Yue, John K. ;
D'Anna, Lucio ;
Huss, Andre ;
Oeckl, Patrick ;
Ludolph, Albert C. ;
Kuhle, Jens ;
Petzold, Axel ;
Manley, Geoffrey T. ;
Green, Ari J. ;
Otto, Markus ;
Tumani, Hayrettin .
NATURE REVIEWS NEUROLOGY, 2022, 18 (03) :158-172
[3]   NfL as a biomarker for neurodegeneration and survival in Parkinson disease [J].
Backstrom, David ;
Linder, Jan ;
Mo, Susanna Jakobson ;
Riklund, Katrine ;
Zetterberg, Henrik ;
Blennow, Kaj ;
Forsgren, Lars ;
Lenfeldt, Niklas .
NEUROLOGY, 2020, 95 (07) :E827-E838
[4]   The dazzling rise of neurofilaments: Physiological functions and roles as biomarkers [J].
Bomont, Pascale .
CURRENT OPINION IN CELL BIOLOGY, 2021, 68 :181-191
[5]   The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study [J].
Chaudhuri, Kallol Ray ;
Martinez-Martin, Pablo ;
Brown, Richard G. ;
Sethi, Kapil ;
Stocchi, Fabrizio ;
Odin, Per ;
Ondo, William ;
Abe, Kazuo ;
MacPhee, Graeme ;
MacMahon, Doug ;
Barone, Paolo ;
Rabey, Martin ;
Forbes, Alison ;
Breen, Kieran ;
Tluk, Susanne ;
Naidu, Yogini ;
Olanow, Warren ;
Williams, Adrian J. ;
Thomas, Sue ;
Rye, David ;
Tsuboi, Yoshio ;
Hand, Annette ;
Schapira, Anthony H. V. .
MOVEMENT DISORDERS, 2007, 22 (13) :1901-1911
[6]   Non-motor symptoms of Parkinson's disease: diagnosis and management [J].
Chaudhuri, KR ;
Healy, DG ;
Schapira, AHV .
LANCET NEUROLOGY, 2006, 5 (03) :235-245
[7]  
Clairembault T, 2014, MOVEMENT DISORD, V29, pS6
[8]   Lack of Appropriate Stoichiometry: Strong Evidence against an Energetically Important Astrocyte-Neuron Lactate Shuttle in Brain [J].
Dienel, Gerald A. .
JOURNAL OF NEUROSCIENCE RESEARCH, 2017, 95 (11) :2103-2125
[9]   Neurofilament light chain as a biomarker in neurological disorders [J].
Gaetani, Lorenzo ;
Blennow, Kaj ;
Calabresi, Paolo ;
Di Filippo, Massimiliano ;
Parnetti, Lucilla ;
Zetterberg, Henrik .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (08) :870-881
[10]   Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS): A new scale for the evaluation of Parkinson's disease [J].
Goetz, C. G. .
REVUE NEUROLOGIQUE, 2010, 166 (01) :1-4